“CMS … spends hundreds of billions of dollars annually on medicines for seniors, disabled people and low-income households through the huge Medicare and Medicaid programs. CMS does not negotiate prices or purchase drugs, but sets ground rules for the managed care companies and state Medicaid agencies that do.”
“Verma said one model under consideration was paying different prices for a single drug based on its success treating a particular condition, such as paying more for a therapy that works better for breast cancer than it does for lung cancer or liver cancer.”
Source: Exclusive: U.S. health regulator Verma eyes new methods for drug pricing – By Caroline Humer, November 30, 2017, Reuters. Read the full article here.
